Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of BLS-M22 in Healthy Volunteers
NCT03789734Phase 1Completed
- Sponsor
- MOA Life Plus Co. Ltd.
- Start
- Jun 2019
- Primary completion
- Apr 2020
- Modality
- Gene Editing, Prophylactic Vaccines, Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BLS-M22 in Duchenne muscular dystrophy (DMD) (4 arms), sponsored by MOA Life Plus Co. Ltd. Primary endpoint: Adverse events. Started Jun 2019; status: completed.
02
Drugs
BLS-M22
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03789734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03789734.